Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 12:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Artery Pressure Clear all
Completed No phase listed Observational

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

NCT04813926
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
49
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 17, 2026, 12:51 PM EDT
Recruiting Not applicable Interventional

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

NCT05934487
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Interventions
Cordella™ Pulmonary Artery Sensor System
Device
Lead sponsor
Endotronix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 17, 2026, 12:51 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

NCT02927366
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
QCC374, Placebo Matching
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 17, 2026, 12:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude

NCT02024386
View directory record Official record
Conditions
Hypertension, Pulmonary, Altitude Sickness
Interventions
Riociguat
Drug
Lead sponsor
Richard Moon
Other
Eligibility
18 Years to 40 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 17, 2026, 12:51 PM EDT
Withdrawn Not applicable Interventional

Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide

NCT01927237
View directory record Official record
Conditions
Low Tidal Volume Ventilation, Acute Respiratory Distress Syndrome
Interventions
HLR, EHR
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 17, 2026, 12:51 PM EDT
Completed No phase listed Observational

Caretaker in the Cardiovascular Intensive Care Unit (CVICU)

NCT05779683
View directory record Official record
Conditions
Cardiac Output, Hemodynamic Monitoring
Interventions
Caretaker Device placement
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 17, 2026, 12:51 PM EDT
Completed Phase 1Phase 2 Interventional

Feasibility of Mid-frequency Ventilation in Newborns With RDS: Randomized Crossover Pilot Trial

NCT01242462
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Conventional Pressure Controlled SIMV, Mid-frequency Ventilation
Procedure · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Hour to 7 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 17, 2026, 12:51 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 17, 2026, 12:51 PM EDT
Withdrawn No phase listed Observational

Pharmacogenomics in Pulmonary Arterial Hypertension

NCT00593905
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
Interventions
Sitaxsentan, Bosentan, Ambrisentan
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 17, 2026, 12:51 PM EDT
Completed Not applicable Interventional

Patient-Executed, Clinician-Confirmed Diuretic Titration in Pulmonary Artery Pressure-Guided Heart Failure (SURPASS-HF)

NCT07743125
View directory record Official record
Conditions
Heart Failure
Interventions
Shared-management diuretic titration guided by remote PA pressure monitoring
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
40 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Menomonee Falls, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 17, 2026, 12:51 PM EDT
Completed Phase 4 Interventional

Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.

NCT01800292
View directory record Official record
Conditions
Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Interventions
sildenafil
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 17, 2026, 12:51 PM EDT
Enrolling by invitation Not applicable Interventional

Vivio At-Home Study

NCT07730268
View directory record Official record
Conditions
Heart Failure
Interventions
Vivio measurement
Diagnostic Test
Lead sponsor
Ventric Health, LLC
Industry
Eligibility
21 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 17, 2026, 12:51 PM EDT
Completed No phase listed Observational

Changes in Hemodynamic Values With Posture

NCT02557009
View directory record Official record
Conditions
Blood Pressure
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 17, 2026, 12:51 PM EDT
Terminated Phase 4 Interventional Results available

Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

NCT02788656
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Implantable Hemodynamic Monitor, Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Type 1 Receptor Blocker, sacubitril/valsartan
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 17, 2026, 12:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Sildenafil Increase Exercise Performance in Air Pollution?

NCT00808912
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Artery Pressure, Exercise Performance, Air Pollution
Interventions
sildenafil, placebo
Drug · Other
Lead sponsor
Marywood University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Sep 17, 2026, 12:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers

NCT01673555
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 17, 2026, 12:51 PM EDT
Withdrawn No phase listed Observational

The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals

NCT02560116
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 17, 2026, 12:51 PM EDT
Active, not recruiting Phase 4 Interventional

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

NCT05203510
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Parenteral Treprostinil, Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 17, 2026, 12:51 PM EDT
Recruiting Not applicable Interventional

The CardioClip Study

NCT06241430
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Mitral Regurgitation
Interventions
CardioMEMS
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 17, 2026, 12:51 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Prevention and Treatment of Immersion Pulmonary Edema

NCT00815646
View directory record Official record
Conditions
Immersion Pulmonary Edema (IPE), Swimming Induced Pulmonary Edema (SIPE)
Interventions
Sildenafil
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Sep 17, 2026, 12:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions

NCT02262689
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK2256294, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 17, 2026, 12:51 PM EDT
Completed Phase 2 Interventional Results available

Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH

NCT02734953
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Nitric Oxide
Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Sep 17, 2026, 12:51 PM EDT
Completed Phase 2 Interventional

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

NCT00109681
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Iloprost Inhalation Solution (Ventavis)
Drug
Lead sponsor
Actelion
Industry
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 17, 2026, 12:51 PM EDT
Completed Not applicable Interventional Results available

Hemodynamic-GUIDEd Management of Heart Failure

NCT03387813
View directory record Official record
Conditions
Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure，Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure; With Decompensation
Interventions
CardioMEMS™ HF System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
125
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 17, 2026, 12:51 PM EDT